-
公开(公告)号：US5618715A
公开(公告)日：1997-04-08
申请号：US75199
申请日：1993-06-10
申请人： Mohammed Shoyab , Joyce M. Zarling , Hans Marquardt , Marcia B. Hanson , Najma Malik , Peter S. Linsley , Timothy M. Rose , Anthony F. Purchio
发明人： Mohammed Shoyab , Joyce M. Zarling , Hans Marquardt , Marcia B. Hanson , Najma Malik , Peter S. Linsley , Timothy M. Rose , Anthony F. Purchio
IPC分类号： A61K38/00 , C07K14/07 , C07K14/475 , C07K14/495 , C07K14/52 , C07K16/22 , C07K16/24 , C12N15/62 , C12N15/73 , C12N5/00 , C07H17/00 , C12N15/00 , C12P21/06
CPC分类号： C07K14/005 , A61K38/191 , A61K38/204 , C07K14/475 , C07K14/495 , C07K14/52 , C07K14/522 , C07K16/22 , C07K16/24 , C12N15/625 , C12N15/73 , C07K2319/00 , C07K2319/02 , C07K2319/50 , C07K2319/75 , C12N2710/24122
摘要： Novel compositions comprising Oncostatin M and congeners thereof, as well as methods for their preparation and methods for their use are provided. The compositions may be prepared by isolation from natural sources, or by recombinant means in either prokaryotic or eukaryotic host cells. In addition, the DNA and polypeptide sequences for Oncostatin M are disclosed. The compositions find use in modulating growth of cells, in particular inhibition of tumor cell proliferation, and stimulation of normal cell growth, especially cells involved in hematopoiesis. Cell growth inhibition compositions may additionally include an adjunctive agent comprising at least one of a transforming growth factor, tumor necrosis factor, or an interferon. Receptors having high affinity for Oncostatin M may additionally be used to screen polypeptides for Oncostatin M-like activity. Methods for use of antibodies to the compositions and probes specific for Oncostatin M mRNA as a means for detecting tumor cells are also provided.
摘要翻译： 提供了包含制瘤素M及其同源物的新型组合物，以及其制备方法及其使用方法。 组合物可以通过从天然来源或通过重组方法在原核或真核宿主细胞中分离来制备。 此外，公开了制瘤素M的DNA和多肽序列。 该组合物可用于调节细胞的生长，特别是抑制肿瘤细胞增殖，刺激正常的细胞生长，特别是涉及造血的细胞。 细胞生长抑制组合物可另外包括包含转化生长因子，肿瘤坏死因子或干扰素中的至少一种的辅助剂。 对制瘤素M具有高亲和力的受体可以另外用于筛选多肽用于制瘤素M样活性。 还提供了使用针对制瘤素M mRNA特异性的组合物和探针的抗体作为肿瘤细胞检测手段的方法。
-
公开(公告)号：US5451506A
公开(公告)日：1995-09-19
申请号：US78707
申请日：1993-06-16
IPC分类号： A61K38/00 , C07K14/07 , C07K14/475 , C07K14/495 , C07K14/52 , C07K16/22 , C07K16/24 , C12N15/62 , C12N15/73 , G01N33/74 , G01N33/60 , G01N33/68 , C07K13/00
CPC分类号： C07K14/005 , A61K38/204 , C07K14/475 , C07K14/495 , C07K14/522 , C07K16/22 , C07K16/24 , C12N15/625 , C12N15/73 , C07K2319/00 , C07K2319/02 , C07K2319/50 , C07K2319/75 , C12N2710/24122 , Y10S435/96
摘要： Novel compositions comprising Oncostatin M and congeners thereof, as well as methods for their preparation and methods for their use are provided. The compositions may be prepared by isolation from natural sources, or by recombinant means in either prokaryotic or eukaryotic host cells. In addition, the DNA and polypeptide sequences for Oncostatin M are disclosed. The compositions find use in modulating growth of cells, in particular inhibition of tumor cell proliferation, and stimulation of normal cell growth, especially cells involved in hematopoiesis. Cell growth inhibition compositions may additionally include an adjunctive agent comprising at least one of a transforming growth factor, tumor necrosis factor, or an interferon. Receptors having high affinity for Oncostatin M may additionally be used to screen polypeptides for Oncostatin M-like activity. Methods for use of antibodies to the compositions and probes specific for Oncostatin M mRNA as a means for detecting tumor cells are also provided.
摘要翻译： 提供了包含制瘤素M及其同源物的新型组合物，以及其制备方法及其使用方法。 组合物可以通过从天然来源或通过重组方法在原核或真核宿主细胞中分离来制备。 此外，公开了制瘤素M的DNA和多肽序列。 该组合物可用于调节细胞的生长，特别是抑制肿瘤细胞增殖，刺激正常的细胞生长，特别是涉及造血的细胞。 细胞生长抑制组合物可另外包括包含转化生长因子，肿瘤坏死因子或干扰素中的至少一种的辅助剂。 对制瘤素M具有高亲和力的受体可以另外用于筛选多肽用于制瘤素M样活性。 还提供了使用针对制瘤素M mRNA特异性的组合物和探针的抗体作为肿瘤细胞检测手段的方法。
-
公开(公告)号：US5428012A
公开(公告)日：1995-06-27
申请号：US85279
申请日：1993-07-01
IPC分类号： A61K38/00 , C07K14/07 , C07K14/475 , C07K14/495 , C07K14/52 , C07K16/22 , C07K16/24 , C12N15/62 , C12N15/73 , C12P21/02 , C12N15/00
CPC分类号： C07K14/005 , A61K38/191 , A61K38/204 , C07K14/475 , C07K14/495 , C07K14/52 , C07K14/522 , C07K16/22 , C07K16/24 , C12N15/625 , C12N15/73 , C07K2319/00 , C07K2319/02 , C07K2319/50 , C07K2319/75 , C12N2710/24122
摘要： Novel compositions comprising Oncostatin M and congeners thereof, as well as methods for their preparation and methods for their use are provided. The compositions may be prepared by isolation from natural sources, or by recombinant means in either prokaryotic or eukaryotic host cells. In addition, the DNA and polypeptide sequences for Oncostatin M are disclosed. The compositions find use in modulating growth of cells, in particular inhibition of tumor cell proliferation, and stimulation of normal cell growth, especially cells involved in hematopoiesis. Cell growth inhibition compositions may additionally include an adjunctive agent comprising at least one of a transforming growth factor, tumor necrosis factor, or an interferon. Receptors having high affinity for Oncostatin M may additionally be used to screen polypeptides for Oncostatin M-like activity. Methods for use of antibodies to the compositions and probes specific for Oncostatin M mRNA as a means for detecting tumor cells are also provided.
-
公开(公告)号：US5120535A
公开(公告)日：1992-06-09
申请号：US46846
申请日：1987-05-04
申请人： Hans Marquardt , Joyce M. Zarling , Mohammed Shoyab , Marcia B. Hanson , Mario N. Lioubin , Thomas J. Brown , Tatsuhiko Ikeda
发明人： Hans Marquardt , Joyce M. Zarling , Mohammed Shoyab , Marcia B. Hanson , Mario N. Lioubin , Thomas J. Brown , Tatsuhiko Ikeda
IPC分类号： A61K38/00 , C07K14/495 , C07K14/52 , C07K16/22 , C07K16/24
CPC分类号： C07K14/52 , A61K38/204 , A61K38/217 , C07K14/495 , C07K16/22 , C07K16/24 , A61K38/00 , C07K2319/75
摘要： Novel compositions are provided for modulating growth, particularly of tumor cells, which compositions are combinations of Oncostatin M, and one or both of transforming growth factors or .gamma.-interferons, or analogs thereof. In addition, a novel transforming growth factor is provided, designated TGF-.beta.2, as well as methods for its preparation.
摘要翻译： 提供新的组合物用于调节生长，特别是肿瘤细胞的生长，该组合物是制瘤素M以及转化生长因子或γ-干扰素之一或两者或其类似物的组合。 此外，提供了一种新的转化生长因子，称为TGF-β2，以及其制备方法。
-
公开(公告)号：US5807734A
公开(公告)日：1998-09-15
申请号：US456221
申请日：1995-05-31
申请人： Michael L. Diegel , Peter S. Linsley , Lisa K. Gilliland , Patricia A. Moran , Joyce M. Zarling , Jeffrey A. Ledbetter
发明人： Michael L. Diegel , Peter S. Linsley , Lisa K. Gilliland , Patricia A. Moran , Joyce M. Zarling , Jeffrey A. Ledbetter
IPC分类号： C12N15/09 , A61K38/00 , A61K39/395 , A61K47/48 , A61P31/12 , A61P31/18 , C07K16/00 , C07K16/28 , C12N1/21 , C12N15/00 , C12N15/13 , C12P21/08 , C12R1/19 , C07H21/04 , C12N1/20 , C12N15/11
CPC分类号： C07K16/2806 , A61K47/48561 , C07K16/00 , A61K38/00 , C07K2317/73 , C07K2319/30
摘要： An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric monoclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional, non-HIV-1-producing T cells in the patient.
摘要翻译： 根据本发明的抗CD2单克隆抗体可以是：（1）通过表达克隆在重组大肠杆菌培养物ATCC No.69277中的构建体产生的嵌合单克隆抗体CD2 SFv-Ig; （2）具有与CD2 SFv-Ig相同的互补决定区的单克隆抗体; 或（3）与CD2 SFv-Ig竞争结合CD2抗原的单克隆抗体与CD2 SFv-Ig按摩尔计有效地至少约80％。 根据本发明的抗CD2单克隆抗体以及可以调节T淋巴细胞和单核细胞之间的相互作用的其它抗体可用于抑制HIV-1感染的HIV-1感染的T细胞在HIV-1中的产生 感染患者。 在另一种用途中，体外治疗的T细胞可以再次输入艾滋病患者，以增加患者功能性，非HIV-1产生的T细胞的比例。
-
公开(公告)号：US5795572A
公开(公告)日：1998-08-18
申请号：US68946
申请日：1993-05-25
申请人： Michael L. Diegel , Peter S. Linsley , Lisa K. Gilliland , Patricia A. Moran , Joyce M. Zarling , Jeffrey A. Ledbetter
发明人： Michael L. Diegel , Peter S. Linsley , Lisa K. Gilliland , Patricia A. Moran , Joyce M. Zarling , Jeffrey A. Ledbetter
IPC分类号： C12N15/09 , A61K38/00 , A61K39/395 , A61K47/48 , A61P31/12 , A61P31/18 , C07K16/00 , C07K16/28 , C12N1/21 , C12N15/00 , C12N15/13 , C12P21/08 , C12R1/19 , A61K39/44 , G01N33/53
CPC分类号： C07K16/2806 , A61K47/48561 , C07K16/00 , A61K38/00 , C07K2317/73 , C07K2319/30
摘要： An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric monoclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional, non-HIV-1-producing T cells in the patient.
-
公开(公告)号：US5081029A
公开(公告)日：1992-01-14
申请号：US304926
申请日：1989-02-01
申请人： Joyce M. Zarling , Shiu-Lok Hu
发明人： Joyce M. Zarling , Shiu-Lok Hu
IPC分类号： A61K35/14 , A61K39/00 , C07K14/16 , C12N5/02 , C12N15/863 , C12N15/866
CPC分类号： C12N15/86 , C07K14/005 , A61K39/00 , C12N2710/14143 , C12N2710/24143 , C12N2740/16022 , C12N2740/16234
摘要： Immunotherapeutic methods for the treatment of patients infected with the AIDS virus are described. T lymphocytes which are histocompatible with the patient and specific for the AIDS virus are activated in vitro by exposure to AIDS virus-related epitopes. Activated T lymphocytes are expanded and inoculated into the patient in order to transfer T cell immunity directed against the AIDS virus epitopes.
摘要翻译： 描述了用于治疗感染AIDS病毒的患者的免疫治疗方法。 与患者组织相容并且针对艾滋病病毒特异性的T淋巴细胞在体外通过暴露于AIDS病毒相关表位而被激活。 将活化的T淋巴细胞扩增并接种到患者体内，以转移针对AIDS病毒表位的T细胞免疫。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.035 秒)
